All Videos

At AAD 2026, Diego Ruiz Dasilva, MD, makes the case that the black box warning on JAK inhibitors shouldn't deter appropriate prescribing.

The inaugural DermVIP Summit will be held from May 8 to 9 at the New York Academy of Medicine.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

Hope Mitchell, MD, shared practical strategies for protecting and cultivating an online presence at the 2026 American Academy of Dermatology Annual Meeting.

Mark Jackson, MD, of Evommune, provides a therapeutic update on the investigational atopic dermatitis drug, citing strong efficacy and safety after just 2 doses, with phase 2b research on the way.

Steven Daveluy, MD, reviews long-term trial data for bimekizumab in psoriasis and hidradenitis suppurativa presented at the 2026 AAD Annual Meeting.

Kimball presented new data on MoonLake Immunotherapeutics’ sonelokimab and reflected on other HS updates presented at AAD 2026.

New HS therapies emerge as JAK inhibitors show trial promise, safer long‑term data, and combo strategies expand options for severe and teen patients.

Why hidradenitis suppurativa patients go undertreated—fatigue, clinician risk fears, and insurance hurdles—plus tips to access modern biologics.

The ongoing phase 2b BROADEN2 study will evaluate KT-621 across 3 dose levels in 200 patients over 16 weeks, with results expected to guide phase 3 dose selection.

At AAD 2026, Andrew Blauvelt, MD, presented robust PASI responses and favorable safety from ONWARD1 and ONWARD2 trials of envudeucitinib, a next-generation TYK2 inhibitor.

At AAD 2026, Christopher Bunick, MD, PhD, and David Cotter, MD, PhD, discuss data suggesting tirzepatide may augment ixekizumab responses in psoriatic arthritis—potentially independent of weight loss.

Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings at AAD highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

Dermatologists tailor seborrheic dermatitis care with shared decisions, steroid-sparing options, combo therapy, and flare-ready expectations.

At AAD 2026, Christopher Bunick, MD, PhD, and Reid Waldman, MD, discuss investigational VDPHL01, extended-release oral minoxidil, for the treatment of women and men with pattern hair loss.

New sunscreen filters, AI tools, and immunotherapies are reshaping skin cancer prevention and treatment, improving precision and long-term survival.

At AAD 2026, Helen He, MD, highlights how minimally invasive molecular profiling distinguishes photoexposed and photoprotected aging trajectories.

At AAD 2026, Melinda Gooderham, MSc, MD, FRCPC, reviewed late-breaking zasocitinib data for psoriasis, noting that 70% of patients reached sPGA 0/1.

Christopher Bunick, MD, PhD, and Kristian Reich, MD, PhD, discuss the long-term efficacy of sonelokimab, with more than 60% of patients achieving HiSCR75 and approximately 30% reaching HiSCR100.

At AAD 2026, Christopher Bunick, MD, PhD, and Patrick Burnett, MD, PhD, discuss late-breaking data of roflumilast cream's improvements in infants with AD.

Pelage’s PP405 novel topical reawakens dormant follicle stem cells, showing signs of terminal regrowth and fueling late-stage alopecia research.

Late-breaking phase 2 findings presented at AAD show nemolizumab achieved high EASI-90 rates and rapid itch relief in pediatric patients with atopic dermatitis.

Nicole Negbenebor, MD, highlights the clinical and professional impact of community-driven education and evidence-based focus in skin of color dermatology.

Christopher Bunick, MD, PhD, interviews medical student Sabine Obagi on the value of conference participation, mentorship, and early exposure for aspiring dermatology clinicians at AAD 2026.

Melanoma cases keep rising, but AI-aided screening, gene profiling, and newer immunotherapies boost early diagnosis and long-term survival, according to Darrell Rigel, MD, MS.

In the final episode, the panel pulls together the clinical “bottom line” from the phase 3 povorcitinib data for hidradenitis suppurativa (HS).

Dermatologists spot hidradenitis suppurativa early, explain it’s inflammatory, and start medical-surgical care and biologics to prevent lasting damage.

Learn how clinicians spot hidradenitis suppurativa early—recurring abscesses, bridging comedones, atypical sites, and when MRI helps distinguish Crohn’s.

In this episode, our panel delves into the safety and tolerability of povorcitinib, specifically addressing the concerns clinicians often face regarding the JAK inhibitor class.